Akari Therapeutics PLC expected to post a loss of $1.20 a share - Earnings Preview

Akari Therapeutics

22/09/2023 13:32

* Akari Therapeutics PLC  AKTX.OQ   AKTX.O  is expected
to report
results on September 22 (estimated).
    * 
    * ​Refinitiv's mean analyst estimate for Akari Therapeutics
PLC is
for a loss of $1.20 per share. 
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Akari
Therapeutics PLC is $55​, above​ its last closing price
of $3.49. ​​​

This summary was machine generated September 22 at 12:32 GMT. 
All figures in US dollars  unless otherwise stated